Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.12.19
Views: 909

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Dr Luca Gianni speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the updated results from the NeoTRIPaPDL1 trial, which examined the addition of atezolizumab with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer.

He describes the main aim of the study and reports that the pathologic complete response rate was similar irrespective of the addition of atezolizumab.

Dr Gianni also discusses the adverse events associated with this regimen and the differences between the use of pembrolizumab and atezolizumab in this disease setting.

He anticipates that data on event-free survival will be available in the next few years and the incorporation of molecular testing in future studies.

Watch the press conference here.

Read more about the study here

Related videos

follow us

CLL Janssen

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation